• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The Durability of Roctavian and the Need for Corticosteroids


Data from clinical trials suggest that the vast majority of the patients respond to the gene therapy for hemophilia A, says Courtney Thornburg, M.D., M.S. But there is also decreasing factor expression.

Second of four parts

In this segment of a video interview with Managed Healthcare Executive, Courtney Thornburg, M.D., M.S., discusses the durability of Roctavian (valoctocogene roxaparvovec) in producing factor VIII and liver inflammation that is treated with corticosteroids.

Thornburg, the medical director of the Hemophilia and Thrombosis Treatment Center at Rady Children’s Hospital-San Diego, was the lead author of a review article about hemophilia gene therapy that was published in July in the journal BioDrugs.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.